Cash from Operations (Quarterly) Chart

View Cash from Operations (Quarterly) for CNBX.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Operations (Quarterly) Chart
Start Trial

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2007. Start Trial.
Date Value
May 31, 2026 -0.0477M
February 28, 2026 -0.0305M
November 30, 2025 -0.0474M
August 31, 2025 -0.0285M
May 31, 2025 -0.052M
February 28, 2025 -0.0517M
November 30, 2024 -0.0391M
August 31, 2024 -0.0482M
May 31, 2024 0.0002M
February 29, 2024 -0.1244M
November 30, 2023 -0.0718M
August 31, 2023 0.0205M
May 31, 2023 -0.0186M
February 28, 2023 -0.0185M
November 30, 2022 -0.0959M
August 31, 2022 -0.1495M
May 31, 2022 -0.3754M
February 28, 2022 -0.5548M
November 30, 2021 -0.5995M
August 31, 2021 -0.5818M
May 31, 2021 -0.6161M
February 28, 2021 -0.7023M
November 30, 2020 -0.5926M
August 31, 2020 -0.714M
May 31, 2020 -0.5757M
Date Value
February 29, 2020 -0.7236M
November 30, 2019 -0.7617M
August 31, 2019 -0.8687M
May 31, 2019 -0.8186M
February 28, 2019 -0.7393M
November 30, 2018 -0.6671M
August 31, 2018 -0.6215M
May 31, 2018 -0.4656M
February 28, 2018 -0.4346M
November 30, 2017 -0.453M
August 31, 2017 -0.3435M
May 31, 2017 -0.2054M
February 28, 2017 -0.1677M
November 30, 2016 -0.147M
August 31, 2016 -0.0694M
May 31, 2016 0.0111M
February 29, 2016 -0.0262M
November 30, 2015 -0.0357M
August 31, 2015 -0.028M
May 31, 2015 0.0156M
February 28, 2015 -0.0571M
November 30, 2014 -0.1096M
August 31, 2014
May 31, 2014 -0.0331M
February 28, 2014 -0.0405M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
Cocrystal Pharma, Inc. -2.536M
GB Sciences, Inc. --
Arvinas, Inc. -48.30M
Fulcrum Therapeutics, Inc. -16.04M
Definium Therapeutics, Inc. -52.33M

Cash from Operations (Quarterly) Related Metrics